92 related articles for article (PubMed ID: 25267471)
1. Downregulation of involucrin in psoriatic lesions following therapy with propylthiouracil, an anti-thyroid thioureylene: immunohistochemistry and gene expression analysis.
Gnanaraj P; Dayalan H; Elango T; Malligarjunan H; Raghavan V; Rao R
Int J Dermatol; 2015 Mar; 54(3):302-6. PubMed ID: 25267471
[TBL] [Abstract][Full Text] [Related]
2. CD1a expression in psoriatic skin following treatment with propylthiouracil, an antithyroid thioureylene.
Elias AN; Nanda VS; Barr RJ
BMC Dermatol; 2003 Jul; 3():3. PubMed ID: 12841851
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy and safety of propylthiouracil in psoriasis: an open-label study.
Gnanaraj P; Malligarjunan H; Dayalan H; Karthikeyan S; Narasimhan M
Indian J Dermatol Venereol Leprol; 2011; 77(6):673-6. PubMed ID: 22016273
[TBL] [Abstract][Full Text] [Related]
4. p16 expression in psoriatic lesions following therapy with propylthiouracil, an antithyroid thioureylene.
Elias AN; Barr RJ; Nanda VS
Int J Dermatol; 2004 Dec; 43(12):889-92. PubMed ID: 15569009
[TBL] [Abstract][Full Text] [Related]
5. Effect of PTU on IL-12 and IL-10 in psoriasis.
Elias AN; Nanda VS; Barr RJ
J Drugs Dermatol; 2003 Dec; 2(6):645-8. PubMed ID: 14711144
[TBL] [Abstract][Full Text] [Related]
6. Propylthiouracil in psoriasis: results of an open trial.
Elias AN; Goodman MM; Liem WH; Barr RJ
J Am Acad Dermatol; 1993 Jul; 29(1):78-81. PubMed ID: 8315081
[TBL] [Abstract][Full Text] [Related]
7. Antioxidant potential of propylthiouracil in patients with psoriasis.
Utaş S; Köse K; Yazici C; Akdaş A; Keleştimur F
Clin Biochem; 2002 May; 35(3):241-6. PubMed ID: 12074833
[TBL] [Abstract][Full Text] [Related]
8. A controlled trial of topical propylthiouracil in the treatment of patients with psoriasis.
Elias AN; Dangaran K; Barr RJ; Rohan MK; Goodman MM
J Am Acad Dermatol; 1994 Sep; 31(3 Pt 1):455-8. PubMed ID: 8077472
[TBL] [Abstract][Full Text] [Related]
9. Serum TNF-alpha in psoriasis after treatment with propylthiouracil, an antithyroid thioureylene.
Elias AN; Nanda VS; Pandian R
BMC Dermatol; 2004 Apr; 4():4. PubMed ID: 15119959
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of propylthiouracil and its influence on prolactin in psoriatic patients.
Malligarjunan H; Gnanaraj P; Subramanian S; Elango T; Dayalan H
Clin Biochem; 2011 Oct; 44(14-15):1209-13. PubMed ID: 21820424
[TBL] [Abstract][Full Text] [Related]
11. Effect of propylthiouracil on adenosine deaminase activity and thyroid function in patients with psoriasis.
Köse K; Utaş S; Yazici C; Akdaş A; Keleştimur F
Br J Dermatol; 2001 Jun; 144(6):1121-6. PubMed ID: 11422030
[TBL] [Abstract][Full Text] [Related]
12. Clinical and immunohistochemical evaluation of psoriatic plaques treated with topical 5-aminolaevulinic acid photodynamic therapy.
Fransson J; Ros AM
Photodermatol Photoimmunol Photomed; 2005 Dec; 21(6):326-32. PubMed ID: 16313245
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of the inhibitor of apoptosis protein survivin in keratinocytes and endothelial cells in psoriasis skin following infliximab therapy.
Markham T; Mathews C; Rogers S; Mullan R; Bresnihan B; Fitzgerald O; Veale DJ; Fearon U
Br J Dermatol; 2006 Dec; 155(6):1191-6. PubMed ID: 17107388
[TBL] [Abstract][Full Text] [Related]
14. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy.
Markham T; Mullan R; Golden-Mason L; Rogers S; Bresnihan B; Fitzgerald O; Fearon U; Veale DJ
J Am Acad Dermatol; 2006 Jun; 54(6):1003-12. PubMed ID: 16713454
[TBL] [Abstract][Full Text] [Related]
15. Oral propylthiouracil for the treatment of resistant plaque psoriasis.
Chowdhury MM; Marks R
J Dermatolog Treat; 2001 Jun; 12(2):81-5. PubMed ID: 12243663
[TBL] [Abstract][Full Text] [Related]
16. Recruitment of cycling epidermal cells and expression of filaggrin, involucrin and tenascin in the margin of the active psoriatic plaque, in the uninvolved skin of psoriatic patients and in the normal healthy skin.
Gerritsen MJ; Elbers ME; de Jong EM; van de Kerkhof PC
J Dermatol Sci; 1997 Mar; 14(3):179-88. PubMed ID: 9138475
[TBL] [Abstract][Full Text] [Related]
17. Abnormal distribution of epidermal protein antigens in psoriatic epidermis.
Watanabe S; Wagatsuma K; Ichikawa E; Takahashi H
J Dermatol; 1991 Mar; 18(3):143-51. PubMed ID: 1715894
[TBL] [Abstract][Full Text] [Related]
18. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study.
Goedkoop AY; Kraan MC; Picavet DI; de Rie MA; Teunissen MB; Bos JD; Tak PP
Arthritis Res Ther; 2004; 6(4):R326-34. PubMed ID: 15225368
[TBL] [Abstract][Full Text] [Related]
19. Tight junction components occludin, ZO-1, and claudin-1, -4 and -5 in active and healing psoriasis.
Peltonen S; Riehokainen J; Pummi K; Peltonen J
Br J Dermatol; 2007 Mar; 156(3):466-72. PubMed ID: 17300235
[TBL] [Abstract][Full Text] [Related]
20. Anti-psoriatic effects of indigo naturalis on the proliferation and differentiation of keratinocytes with indirubin as the active component.
Lin YK; Leu YL; Yang SH; Chen HW; Wang CT; Pang JH
J Dermatol Sci; 2009 Jun; 54(3):168-74. PubMed ID: 19303259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
